Small Indian Drug Makers Fear Institution Trend To Favor Big Pharma
This article was originally published in PharmAsia News
Indian Railways applies "restrictive purchase policies" on pharmaceuticals, according to some of the smaller drug makers. The group said the company's decision, expected to become effective in mid-September, to cover drugs dispensed in hospitals that buy only from the larger manufacturers discriminates against the smaller firms. That segment of the industry fears a trend in India by companies to follow the example of the Steel Authority of India, another government-supported institution, and adopt similar practices. (Click here for more
You may also be interested in...
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.
GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.
Manufacturers warned to keep better electronic records and not falsify data in recent warning letters, ICH adds three residual solvent limits for pharmaceuticals, and the Polish authority hits firm for GMP noncompliance.